Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.

Abstract

Platinum chemotherapy, particularly cisplatin, is commonly associated with electrolyte imbalances, including hypomagnesemia, hypokalemia, hypophosphatemia, hypocalcemia and hyponatremia. The corpus of literature on these dyselectrolytemias is large; the objective of this review is to synthesize the literature and summarize the mechanisms responsible for these particular electrolyte disturbances in the context of platinum-based treatment as well as to present the clinical manifestations and current management strategies for oncologists and primary care physicians, since the latter are increasingly called on to provide care for cancer patients with medical comorbidities. Correct diagnosis and effective treatment are essential to improved patient outcomes.

• Authors: Bryan Oronsky, Scott Caroen, Arnold Oronsky, Vaughn E Dobalian, Neil Oronsky, Michelle Lybeck, Tony R Reid, Corey A Carter
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 80 Issue 5 Pg. 895-907 (Nov 2017) ISSN: 1432-0843 [Electronic] Germany
• PMID: 28730291 (Publication Type: Journal Article, Review)

Chemical References

• Platinum

Topics

• Humans
• Neoplasms (drug therapy)
• Platinum (therapeutic use)
• Water-Electrolyte Imbalance (drug therapy)